AccessibilityHelpAbout Us
Lumos Diagnostics logo

Lumos Diagnostics(ASX) LDX

Market CapA$94.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 Year-91%
1 Year-29%
1 Month-13%
A$0.10
+0.00%
+0.00Today
Lumos Diagnostics last closing stock price
MetricPriceDate
Last closeAUD 0.102026-09-11
Lumos Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.76%AUD 0.112026-09-04
1 month-13.04%AUD 0.122026-08-12
3 month-4.76%AUD 0.112026-06-12
Year to date-64.91%AUD 0.292025-12-31
1 year-28.57%AUD 0.142025-09-11
3 year+6.38%AUD 0.092023-09-12
5 year-91.3%AUD 1.152021-09-10
Since inception-91.17%AUD 1.132021-07-05

Lumos Diagnostics Financials at a Glance

Market Cap

A$94.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$25.60M

Net Income (TTM)

-$12.22M

EPS (TTM)

-A$0.01

P/E Ratio

-10.20

Dividend

A$0.00

Beta (Volatility)

0.03 (Low)

Price

A$0.10

Volume

2,083,408

Open

A$0.10

Previous Close

A$0.10

Daily Range

A$0.10 - A$0.10

52-Week Range

A$0.08 - A$0.33

Estimated Earnings Date

Mar 4, 2027

LDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lumos Diagnostics

Lumos Diagnostics Holdings Limited specializes in developing, manufacturing, and commercializing point-of-care diagnostic products aimed at managing infectious diseases. The company is based in Carlsbad, California, and focuses on innovative solutions for rapid diagnosis in the healthcare sector.

Products and Services
  • FebriDx: A test for differentiating viral and bacterial respiratory infections
  • ViraDx: A three-in-one test for influenza A, influenza B, and COVID-19
  • Assay development and manufacturing services for point-of-care tests
Growth Outlook
  • Increasing demand for rapid diagnostic solutions in healthcare
  • Expansion into new markets expected to drive revenue growth
  • Innovative product pipeline aimed at enhancing diagnostic capabilities
Financial Highlights
  • Recent quarterly revenue of 6.23 million, showing growth potential
  • Trailing twelve months (TTM) revenue of 25.5 million, indicating market traction
  • Cash and cash equivalents of 2.99 million, providing operational liquidity
Lumos Diagnostics Holdings Limited is positioned in a growing market with a focus on innovative diagnostic solutions. The company's products, such as FebriDx and ViraDx, cater to the increasing need for rapid and accurate testing, particularly in the context of infectious diseases. The growth outlook is bolstered by expanding market opportunities and a robust product pipeline, which may enhance the company's competitive edge. Financially, Lumos Diagnostics has demonstrated promising revenue figures, with a recent quarterly revenue of 6.23 million and a TTM revenue of 25.5 million. This performance reflects the company's ability to capture market share and respond to the rising demand for point-of-care diagnostics. Additionally, the company maintains a cash position of 2.99 million, which supports ongoing operations and potential growth initiatives. Overall, Lumos Diagnostics Holdings Limited presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the diagnostics space.
AI Generated • Aug 21, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Douglas Ward

Website

www.lumosdiagnostics.com

Headquarters

Melbourne, VIC 3000, AU

LDX Financials

Key Financial Metrics (TTM)

Gross Margin

-58.54%

Operating Margin

-107.10%

Net Income Margin

-38.18%

Return on Equity

-35.89%

Return on Capital

-50.16%

Return on Assets

-12.37%

Earnings Yield

-9.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$94.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

945.12M

Volume

2.08M

Avg. Volume

2.18M

Financials (TTM)

Gross Profit

-$50.02K

Operating Income

-$19.68M

EBITDA

-$17.66M

Operating Cash Flow

-$8.36M

Capital Expenditure

-$2.55M

Free Cash Flow

-$10.91M

Cash & ST Invst.

$15.42M

Total Debt

$5.94M

Lumos Diagnostics Performance Analysis

Lumos Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 15,660,665-2.3%
20242024-06-30USD 16,984,1698.5%
20252025-06-30USD 19,146,70612.7%
20262026-06-30USD 19,468,0541.7%
Lumos Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30-24.6%
Q42025-06-30-3.4%
Q22025-12-312.3%
Q42026-06-3011.9%
Lumos Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.05-86.3%
20242024-06-30USD -0.03-50.1%
20252025-06-30USD -0.02-38.7%
20262026-06-30USD -0.01-44.8%
Lumos Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30N/A
Q42025-06-30-26.1%
Q22025-12-31-10.3%
Q42026-06-30103.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$6.97M

-16.7%

Gross Profit

-$4.65M

-190.7%

Gross Margin

-66.76%

N/A

Market Cap

A$94.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.26M

N/A

Employees

29

N/A

Net Income

-$70.97K

+96.7%

EBITDA

-$6.26M

-352.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$15.42M

+138.0%

Total Debt

$5.94M

-26.3%

Accounts Receivable

$2.22M

+230.2%

Inventory

$1.64M

+109.2%

Long Term Debt

$4.88M

-31.4%

Short Term Debt

$1.06M

+11.3%

Return on Assets

-12.37%

N/A

Return on Invested Capital

-51.00%

N/A

Free Cash Flow

-$2.11M

-136.8%

Operating Cash Flow

$192.10K

-96.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AHC.AXAustco Healthcare Limited
A$0.27+0.00%
SOM.AXSomnoMed Limited
A$0.33-1.49%
PAR.AXParadigm Biopharmaceuticals Limited
A$0.24-15.79%
ONE.AXOneview Healthcare PLC
A$0.17+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About LDX

What is the current price of Lumos Diagnostics?

Lumos Diagnostics is trading at A$0.10 per share.

What is the 52-week range for Lumos Diagnostics?

Over the past 52 weeks, Lumos Diagnostics has traded between A$0.08 and A$0.33.

How much debt does Lumos Diagnostics have?

As of the most recent reporting period, Lumos Diagnostics reported total debt of $8.57M.

How much cash does Lumos Diagnostics have on hand?

Lumos Diagnostics reported $22.27M in cash and cash equivalents in its most recent financial results.

What is Lumos Diagnostics’s dividend yield?

Lumos Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services